Determination and control of TEMPO, a potentially genotoxic free radical reagent used in the synthesis of filibuvir

Journal of Pharmaceutical and Biomedical Analysis

Volumn 62, Issue , 2012, Pages 216-219

  Strohmeyer, Holly E ^a   Sluggett, Gregory W ^a  

^a PFIZER INC   (United States)

Author keywords

Filibuvir; GC MS; Genotoxic impurity; TEMPO

Indexed keywords

2,2,6,6 TETRAMETHYL 1 PIPERIDINYLOXY; FILIBUVIR; FREE RADICAL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG IMPURITY; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; GENOTOXICITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ANTIVIRAL AGENTS; CYCLIC N-OXIDES; FREE RADICALS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; INDICATORS AND REAGENTS; LIMIT OF DETECTION; MUTAGENS; PYRONES; RNA REPLICASE; TRIAZOLES;

EID: 84857139639     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.12.036     Document Type: Article

References (23)

1. Hui L., Tatlock J., Linton A., Gonzalez J., Jewell T., Patel L., Ludlum S., Drowns M., Rahavendran S.V., Skor H., Hunter R., Shi S.T., Herlihy K.J., Parge H., Hickey M., Yu X., Chau F., Nonomiya J., Lewis C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. 2009, 52:1255-1258.
2. Camp D., Matthews C.F., Neville S.T., Rouns M., Scott R.W., Truong Y. Development of a synthetic process towards a hepatitis C polymerase inhibitor. Org. Process Res. Dev. 2006, 10:814-821.
3. Genotoxic Impurities Strategies for Identification and Control 2010, John Wiley & Sons, Hoboken, NJ. A. Teasdale (Ed.).
4. Guideline on the Limits of Genotoxic Impurities, Committee for Medicinal Products for Human Use (CHMP) 28 June 2006, European Medicines Agency, London, (CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006).
5. Guidance for Industry, Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches December 2008, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
6. Muller L., Mauthe R.J., Riley C.M., Andino M.A., De Antonis D., Beels C., DeGeorge J., De Knaep A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., Yotti L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 2006, 44:198-211.
7. Questions & Answers on the " Guideline on the Limits of Genotoxic Impurities" 2010, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, (EMA/CHMP/SWP/431994/2007).
8. Deductive Estimation of Risk from Existing Knowledge (DEREK), marketed by LHASA Ltd., Leeds, UK, https://www.lhasalimited.org/.
9. Gallez B., De Meester C., Debuyst R., Dejehet F., Dumont P. Mutagenicity of nitroxyl compounds: structure-activity relationships. Toxicol. Lett. 1992, 63:35-45.
10. Damiani E., Greci L., Hrella P. Cyto- and genotoxic effects of novel aromatic nitroxide radicals in vitro. Free Radic. Biol. Med. 2000, 28:330-336.
11. Sun M., Liu D.Q., Kord A.S. A systematic method development strategy for determination of pharmaceutical genotoxic impurities. Org. Process Res. Dev. 2010, 14:977-985.
12. Liu D.Q., Sun M., Kord A.S. Recent advances in trace analysis of pharmaceutical genotoxic impurities. J. Pharm. Biomed. Anal. 2010, 51:999-1014.
13. Raman N.V.V.S.S., Prasad A.V.S.S., Reddy K.R. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2011, 55:662-667.
14. Pierson D.A., Olsen B.A., Robbins D.K., DeVries K.M., Varie D.L. Approaches to assessment, testing decisions, and analytical determination of genotoxic impurities in drug substances. Org. Process Res. Dev. 2009, 13:285-291.
15. Robinson D.I. Control of genotoxic impurities in active pharmaceutical ingredients: a review and perspective. Org. Process Res. Dev. 2010, 14:946-959.
16. Looker A.R., Ryan M.P., Neubert-Langille B.J., Naji R. Risk assessment of potentially genotoxic impurities within the framework of quality by design. Org. Process Res. Dev. 2010, 14:1032-1036.
17. De Mico A., Margarita R., Parlanti L., Vescovi A., Piancatelli G. A versatile and highly selective hypervalent iodine (III)/2,2,6,6-tetramethyl-1-piperidinyloxyl-mediated oxidation of alcohols to carbonyl compounds. J. Org. Chem. 1997, 62:6974-6977.
18. Henry-Riyad H., Tidwell T.T. Thermolysis of N-tetramethylpiperidinyl triphenylacetate: hemolytic fragmentation of a TEMPO ester. J. Phys. Org. Chem. 2003, 16:559-563.
19. Hunter D.H., Racok J.S., Rey A.W., Ponce Y.Z. Oxoiminium ions for N-demethylation: 1-oxo-2,2,6,6-teteramethylpiperidinium chloride. J. Org. Chem. 1988, 53:1278-1281.
20. Root K.S., Hill C.L., Lawrence L.M., Whitesides G.M. The mechanism of formation of Grignard reagents: trapping of free alkyl radical intermediates by reaction with tetramethylpiperidine-N-oxyl. J. Am. Chem. Soc. 1989, 111:5405-5412.
21. Montanari F., Quici S. 2,2,6,6-Tetramethylpiperidin-1-oxyl. Encyclopedia of Reagents for Organic Synthesis 1995, 4821-4823. John Wiley & Sons, New York. L.A. Paquette (Ed.).
22. Li H., Sluggett G.W. Development and validation of a sensitive GC-MS method for the determination of trace levels of an alkylating reagent in a β-lactam active pharmaceutical ingredient. J. Pharm. Biomed. Anal. 2005, 39:486-494.
23. Teasdale A., Fenner S., Ray A., Ford A., Phillips A. A tool for the semiquantitative assessment of potentially genotoxic impurity (PGI) carryover into API using physicochemical parameters and process conditions. Org. Process Res. Dev. 2010, 14:943-945.